Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Cardiovascular & Haematological Disorders - Drug Targets
  4. Fast Track Articles
  5. Fast Track Article
image of Treating Cardiovascular Disorders with Personalized Medicine

Abstract

The past decade has appreciated personalized medicine as a novel medical approach that deals with all practices that are tailored to individual patients. Personalized treatment or personalized cardiology for cardiovascular disorders is an emerging medicine system for related patients. Personalized cardiology is solely based on genomics and proteomics; molecular diagnostics and biomarkers of the cardiovascular system link diagnosis with therapy. Bioinformatics is useful in CVD risk stratification and might improve risk-estimating algorithms. Personalized cardiology involves 3D printing, pharmacotherapy, surgery, lifestyle modifications, and combinations thereof. Understanding the pathology of CVD and identifying causative factors at the individual level can provide opportunities for developing personalized medicine. Since it offers novel avenues for diagnosing, preventing, and treating CVD, molecular genetics has made a substantial contribution to the field of molecular cardiology. Nonetheless, there are still a lot of obstacles to overcome from the standpoints of science and policy. These obstacles can be avoided using evidence-based procedures, clinical applications, biomarker-based detection techniques, comprehensive concepts, and understanding. Targeted therapies may be developed as a result of improved disease classification and a better knowledge of the individual differences in pathology. Cardiovascular disorders, like hypertension, angina, or ischemic heart, a condition of reduced blood flow to the heart, coronary artery disease or damaged blood vessels, myocardial infarction or resisted blood flow to the myocardium, and cardiac arrhythmia or irregular cardiac cycles are the primary targets for personalized cardiology. The current review discusses various parameters for personalizing the treatment of cardiovascular disorders.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X361429250215190129
2025-02-25
2025-05-13

  • From This Site

    /content/journals/chddt/10.2174/011871529X361429250215190129
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. The shift from personalized medicine to precision medicine and precision public health. 2016 Available from: https://blogs.cdc.gov/genomics/2016/04/21/shift/
  2. Genetics 2024 Available from: https://medlineplus.gov/ency/article/002048.htm
  3. Di Sanzo M. Cipolloni L. Borro M. La Russa R. Santurro A. Scopetti M. Simmaco M. Frati P. Clinical applications of personalized medicine: A new paradigm and challenge. Curr. Pharm. Biotechnol. 2017 18 3 194 203 10.2174/1389201018666170224105600 28240172
    [Google Scholar]
  4. Vogenberg F.R. Isaacson Barash C. Pursel M. Personalized medicine: Part 1: Evolution and development into theranostics. P&T 2010 35 10 560 576 21037908
    [Google Scholar]
  5. Vogenberg F.R. Barash C.I. Pursel M. Personalized medicine: part 2: Ethical, legal, and regulatory issues. P&T 2010 35 11 624 642 21139819
    [Google Scholar]
  6. Jakka S. Rossbach M. An economic perspective on personalized medicine. HUGO J. 2013 7 1 1 6 10.1186/1877‑6566‑7‑1
    [Google Scholar]
  7. Sadée W. Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 2005 14 Suppl. 2 R207 R214 10.1093/hmg/ddi261 16244319
    [Google Scholar]
  8. Abrahams E. Ginsburg G.S. Silver M. The personalized medicine coalition. Am. J. Pharmacogenomics 2005 5 6 345 355 10.2165/00129785‑200505060‑00002 16336000
    [Google Scholar]
  9. Vu T. Claret F.X. Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2012 2 62 10.3389/fonc.2012.00062 22720269
    [Google Scholar]
  10. Mathur S. Sutton J. Personalized medicine could transform healthcare. Biomed. Rep. 2017 7 1 3 5 10.3892/br.2017.922 28685051
    [Google Scholar]
  11. Mali P. Esvelt K.M. Church G.M. Cas9 as a versatile tool for engineering biology. Nat. Methods 2013 10 10 957 963 10.1038/nmeth.2649 24076990
    [Google Scholar]
  12. Miedany Y.E. MABS: Targeted therapy tailored to the patient’s need. Br. J. Nurs. 2015 24 Sup16a Suppl. 1 S4 S13 10.12968/bjon.2015.24.Sup16a.S4 26946646
    [Google Scholar]
  13. Florence A.T. Lee V.H.L. Personalised medicines: More tailored drugs, more tailored delivery. Int. J. Pharm. 2011 415 1-2 29 33 10.1016/j.ijpharm.2011.04.047 21565262
    [Google Scholar]
  14. Jain KK Textbook of Personalized Medicine. Springer
    [Google Scholar]
  15. Jain K.K. Pharmabiotech J. Personalized management of cardiovascular disorders. Med. Princ. Pract. 2017 26 5 399 414 10.1159/000481403 28898880
    [Google Scholar]
  16. Shapiro S.D. Merging personalized medicine and biology of aging in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011 184 8 864 866 10.1164/rccm.201108‑1486ED 22003144
    [Google Scholar]
  17. Piquette-Miller M. Grant D.M. The art and science of personalized medicine. Clin. Pharmacol. Ther. 2007 81 3 311 315 10.1038/sj.clpt.6100130 17339856
    [Google Scholar]
  18. Lunshof J.E. Pirmohamed M. Gurwitz D. Personalized medicine: Decades away? Pharmacogenomics 2006 7 2 237 241 10.2217/14622416.7.2.237 16515403
    [Google Scholar]
  19. Belmont JW Hardenbol P Willis TD Yu F Yang H The International HapMap project Nature 2003 426 6968 789 796 10.1038/nature02168
    [Google Scholar]
  20. Guttmacher A.E. Collins F.S. Genomic medicine--A primer. N. Engl. J. Med. 2002 347 19 1512 1520 10.1056/NEJMra012240 12421895
    [Google Scholar]
  21. Manace L.C. Godiwala T.N. Babyatsky M.W. Genomics of cardiovascular disease. Mt. Sinai J. Med. 2009 76 6 613 623 10.1002/msj.20151 20014425
    [Google Scholar]
  22. Lee M.S. Flammer A.J. Lerman L.O. Lerman A. Personalized medicine in cardiovascular diseases. Korean Circ. J. 2012 42 9 583 591 10.4070/kcj.2012.42.9.583 23091501
    [Google Scholar]
  23. Bonter K. Desjardins C. Currier N. Pun J. Ashbury F.D. Personalised medicine in Canada: A survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 2011 1 1 e000110 10.1136/bmjopen‑2011‑000110 22021765
    [Google Scholar]
  24. Zineh I. Pebanco G.D. Aquilante C.L. Gerhard T. Beitelshees A.L. Beasley B.N. Hartzema A.G. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann. Pharmacother. 2006 40 4 639 644 10.1345/aph.1G464 16595569
    [Google Scholar]
  25. Ginsburg G. McCarthy J.J. Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol. 2001 19 12 491 496 10.1016/S0167‑7799(01)01814‑5 11711191
    [Google Scholar]
  26. Tracy T. Wu L. Liu X. Cheng S. Li X. 3D printing: Innovative solutions for patients and pharmaceutical industry. Int. J. Pharm. 2023 631 122480 10.1016/j.ijpharm.2022.122480 36509225
    [Google Scholar]
  27. Spritam (levetiracetam) FDA Approval History. 2023 Available from: https://www.drugs.com/history/spritam.html#:~:text=Spritam%20FDA%20Approval%20History&text=Levetiracetam%20was%20first%20approved%20under,with%20a%20sip%20of%20liquid.
  28. Sandanamsamy L. Harun W.S.W. Ishak I. Romlay F.R.M. Kadirgama K. Ramasamy D. Idris S.R.A. Tsumori F. A comprehensive review on fused deposition modelling of polylactic acid. Prog Addit Manuf 2023 8 5 775 799 10.1007/s40964‑022‑00356‑w 38625345
    [Google Scholar]
  29. Seoane-Viaño I. Januskaite P. Alvarez-Lorenzo C. Basit A.W. Goyanes A. Semi-solid extrusion 3D printing in drug delivery and biomedicine: Personalised solutions for healthcare challenges. J. Control. Release 2021 332 367 389 10.1016/j.jconrel.2021.02.027 33652114
    [Google Scholar]
  30. Bandari S. Nyavanandi D. Dumpa N. Repka M.A. Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance. Adv. Drug Deliv. Rev. 2021 172 52 63 10.1016/j.addr.2021.02.006 33571550
    [Google Scholar]
  31. Chen X Wang S Wu J Duan S Wang X Hong X The application and challenge of Binder Jet 3D printing technology in pharmaceutical manufacturing. Pharmaceutics 2022 14 12 2589 10.3390/pharmaceutics14122589
    [Google Scholar]
  32. Awad A. Fina F. Goyanes A. Gaisford S. Basit A.W. Advances in powder bed fusion 3D printing in drug delivery and healthcare. Adv. Drug Deliv. Rev. 2021 174 406 424 10.1016/j.addr.2021.04.025 33951489
    [Google Scholar]
  33. Mukhtarkhanov M Perveen A Talamona D. Application of stereolithography based 3D printing technology in investment casting. Micromachines 2020 11 10 946 10.3390/mi11100946
    [Google Scholar]
  34. Mancilla-De-la-Cruz J. Rodriguez-Salvador M. An J. Chua C.K. Three-dimensional printing technologies for drug delivery applications: Processes, materials, and effects. IJB 2022 8 4 622 10.18063/ijb.v8i4.622 36404786
    [Google Scholar]
  35. Khaled S.A. Burley J.C. Alexander M.R. Yang J. Roberts C.J. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. J. Control. Release 2015 217 308 314 10.1016/j.jconrel.2015.09.028 26390808
    [Google Scholar]
  36. Lafeber M. Grobbee D.E. Bots M.L. Thom S. Webster R. Rodgers A. Visseren F.L.J. Spiering W. The evening versus morning polypill utilization study: The TEMPUS rationale and design. Eur. J. Prev. Cardiol. 2014 21 4 425 433 10.1177/2047487313476961 23382539
    [Google Scholar]
  37. Carey K.M. Cornee M.R. Donovan J.L. Kanaan A.O. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann. Pharmacother. 2012 46 5 688 695 10.1345/aph.1Q621 22570437
    [Google Scholar]
  38. Hippisley-Cox J. Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: Nested case-control analysis. BMJ 2005 330 7499 1059 1063 10.1136/bmj.330.7499.1059 15879390
    [Google Scholar]
  39. Yusuf S. Pais P. Afzal R. Xavier D. Teo K. Eikelboom J. Sigamani A. Mohan V. Gupta R. Thomas N. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet 2009 373 9672 1341 1351 10.1016/S0140‑6736(09)60611‑5 19339045
    [Google Scholar]
  40. Polycap capsule: View uses, side effects, price and substitutes 2023 Available from: https://www.1mg.com/drugs/polycap-capsule-165295#:~:text=Polycap%20Capsule%20is%20used%20for,It%20may%20cause%20dizziness.
  41. Schneeberger A. 3D screen printing enables application of integrated QR codes on pharmaceutical dosage forms in mass production – A game changer. Biomed. J. Sci. Tech. Res. 2022 41 4 10.26717/BJSTR.2022.41.006630
    [Google Scholar]
  42. Karavasili C. Zgouro P. Manousi N. Lazaridou A. Zacharis C.K. Bouropoulos N. Moschakis T. Fatouros D.G. Cereal-based 3D printed dosage forms for drug administration during breakfast in pediatric patients within a hospital setting. J. Pharm. Sci. 2022 111 9 2562 2570 10.1016/j.xphs.2022.04.013 35469835
    [Google Scholar]
  43. Polak-Iwaniuk A. Harasim-Symbor E. Gołaszewska K. Chabowski A. How hypertension affects heart metabolism. Front. Physiol. 2019 10 435 10.3389/fphys.2019.00435 31040794
    [Google Scholar]
  44. Tsibulnikov S.Y. Maslov L.N. Gorbunov A.S. Voronkov N.S. Boshchenko A.A. Popov S.V. Prokudina E.S. Singh N. Downey J.M. A review of humoral factors in remote preconditioning of the heart. J. Cardiovasc. Pharmacol. Ther. 2019 24 5 403 421 10.1177/1074248419841632 31035796
    [Google Scholar]
  45. Structure of the Heart. 2023 Available from: https://training.seer.cancer.gov/anatomy/cardiovascular/heart/structure.html#:~:text=The%20human%20heart%20is%20a,layers%20of%20a%20serous%20membrane
  46. Mollova M. Bersell K. Walsh S. Savla J. Das L.T. Park S.Y. Silberstein L.E. dos Remedios C.G. Graham D. Colan S. Kühn B. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc. Natl. Acad. Sci. USA 2013 110 4 1446 1451 10.1073/pnas.1214608110 23302686
    [Google Scholar]
  47. Gruzdeva O.V. Borodkina D.A. Belik E.V. Akbasheva O.E. Palicheva E.I. Barbarash O.L. Ghrelin physiology and pathophysiology: Focus on the cardiovascular system. Kardiologiia 2019 59 3 60 67 10.18087/cardio.2019.3.10220 30990143
    [Google Scholar]
  48. Seo D.Y. Kwak H.B. Kim A.H. Park S.H. Heo J.W. Kim H.K. Ko J.R. Lee S.J. Bang H.S. Sim J.W. Kim M. Han J. Cardiac adaptation to exercise training in health and disease. Pflugers Arch. 2020 472 2 155 168 10.1007/s00424‑019‑02266‑3 31016384
    [Google Scholar]
  49. Park S. Nguyen N.B. Pezhouman A. Ardehali R. Cardiac fibrosis: Potential therapeutic targets. Transl. Res. 2019 209 121 137 10.1016/j.trsl.2019.03.001 30930180
    [Google Scholar]
  50. Saxton A. Chaudhry R. Manna B. Anatomy, Thorax, Heart Right Coronary Arteries. StatPearls 2023
    [Google Scholar]
  51. Hussain A. Burns B. Anatomy, Thorax, Wall. StatPearls 2023
    [Google Scholar]
  52. Buckberg G.D. Nanda N.C. Nguyen C. Kocica M.J. What is the heart? anatomy, function, pathophysiology, and misconceptions. J. Cardiovasc. Dev. Dis. 2018 5 2 33 10.3390/jcdd5020033 29867011
    [Google Scholar]
  53. Fedele L. Brand T. The intrinsic cardiac nervous system and its role in cardiac pacemaking and conduction. J. Cardiovasc. Dev. Dis. 2020 7 4 54 10.3390/jcdd7040054 33255284
    [Google Scholar]
  54. Bhattacharyya S. Munshi N.V. Development of the cardiac conduction system. Cold Spring Harb. Perspect. Biol. 2020 12 12 a037408 10.1101/cshperspect.a037408 31988140
    [Google Scholar]
  55. Chan I.S. Ginsburg G.S. Personalized medicine: Progress and promise. Annu. Rev. Genomics Hum. Genet. 2011 12 1 217 244 10.1146/annurev‑genom‑082410‑101446 21721939
    [Google Scholar]
  56. Thomas M. Lieberman J. Lal A. Desperately seeking microRNA targets. Nat. Struct. Mol. Biol. 2010 17 10 1169 1174 10.1038/nsmb.1921 20924405
    [Google Scholar]
  57. Roden D.M. Altman R.B. Benowitz N.L. Flockhart D.A. Giacomini K.M. Johnson J.A. Krauss R.M. McLeod H.L. Ratain M.J. Relling M.V. Ring H.Z. Shuldiner A.R. Weinshilboum R.M. Weiss S.T. Pharmacogenomics: Challenges and opportunities. Ann. Intern. Med. 2006 145 10 749 757 10.7326/0003‑4819‑145‑10‑200611210‑00007 17116919
    [Google Scholar]
  58. Azizan E.A.B. Poulsen H. Tuluc P. Zhou J. Clausen M.V. Lieb A. Maniero C. Garg S. Bochukova E.G. Zhao W. Shaikh L.H. Brighton C.A. Teo A.E.D. Davenport A.P. Dekkers T. Tops B. Küsters B. Ceral J. Yeo G.S.H. Neogi S.G. McFarlane I. Rosenfeld N. Marass F. Hadfield J. Margas W. Chaggar K. Solar M. Deinum J. Dolphin A.C. Farooqi I.S. Striessnig J. Nissen P. Brown M.J. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet. 2013 45 9 1055 1060 10.1038/ng.2716 23913004
    [Google Scholar]
  59. Jørgensen A.B. Frikke-Schmidt R. Nordestgaard B.G. Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 2014 371 1 32 41 10.1056/NEJMoa1308027 24941082
    [Google Scholar]
  60. Crosby J. Peloso G.M. Auer P.L. Crosslin D.R. Stitziel N.O. Lange L.A. Lu Y. Tang Z.Z. Zhang H. Hindy G. Masca N. Stirrups K. Kanoni S. Do R. Jun G. Hu Y. Kang H.M. Xue C. Goel A. Farrall M. Duga S. Merlini P.A. Asselta R. Girelli D. Olivieri O. Martinelli N. Yin W. Reilly D. Speliotes E. Fox C.S. Hveem K. Holmen O.L. Nikpay M. Farlow D.N. Assimes T.L. Franceschini N. Robinson J. North K.E. Martin L.W. DePristo M. Gupta N. Escher S.A. Jansson J.H. Van Zuydam N. Palmer C.N. Wareham N. Koch W. Meitinger T. Peters A. Lieb W. Erbel R. Konig I.R. Kruppa J. Degenhardt F. Gottesman O. Bottinger E.P. O’Donnell C.J. Psaty B.M. Ballantyne C.M. Abecasis G. Ordovas J.M. Melander O. Watkins H. Orho-Melander M. Ardissino D. Loos R.J. McPherson R. Willer C.J. Erdmann J. Hall A.S. Samani N.J. Deloukas P. Schunkert H. Wilson J.G. Kooperberg C. Rich S.S. Tracy R.P. Lin D.Y. Altshuler D. Gabriel S. Nickerson D.A. Jarvik G.P. Cupples L.A. Reiner A.P. Boerwinkle E. Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 2014 371 1 22 31 10.1056/NEJMoa1307095 24941081
    [Google Scholar]
  61. Wilde A.A.M. Bezzina C.R. Genetics of cardiac arrhythmias. Heart 2005 91 10 1352 1358 10.1136/hrt.2004.046334 16162633
    [Google Scholar]
  62. Roden D.M. Balser J.R. George A.L. Jr Anderson M.E. Cardiac ion channels. Annu. Rev. Physiol. 2002 64 1 431 475 10.1146/annurev.physiol.64.083101.145105 11826275
    [Google Scholar]
  63. Clancy C.E. Kass R.S. Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels. Physiol. Rev. 2005 85 1 33 47 10.1152/physrev.00005.2004 15618477
    [Google Scholar]
  64. Mohler P.J. Schott J.J. Gramolini A.O. Dilly K.W. Guatimosim S. duBell W.H. Song L.S. Haurogné K. Kyndt F. Ali M.E. Rogers T.B. Lederer W.J. Escande D. Marec H.L. Bennett V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003 421 6923 634 639 10.1038/nature01335 12571597
    [Google Scholar]
  65. Plaster N.M. Tawil R. Tristani-Firouzi M. Canún S. Bendahhou S. Tsunoda A. Donaldson M.R. Iannaccone S.T. Brunt E. Barohn R. Clark J. Deymeer F. George A.L. Jr Fish F.A. Hahn A. Nitu A. Ozdemir C. Serdaroglu P. Subramony S.H. Wolfe G. Fu Y.H. Ptáček L.J. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell 2001 105 4 511 519 10.1016/S0092‑8674(01)00342‑7 11371347
    [Google Scholar]
  66. Splawski I. Timothy K.W. Sharpe L.M. Decher N. Kumar P. Bloise R. Napolitano C. Schwartz P.J. Joseph R.M. Condouris K. Tager-Flusberg H. Priori S.G. Sanguinetti M.C. Keating M.T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004 119 1 19 31 10.1016/j.cell.2004.09.011 15454078
    [Google Scholar]
  67. Olson T.M. Michels V.V. Ballew J.D. Reyna S.P. Karst M.L. Herron K.J. Horton S.C. Rodeheffer R.J. Anderson J.L. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005 293 4 447 454 10.1001/jama.293.4.447 15671429
    [Google Scholar]
  68. Bezzina C. Veldkamp M.W. van den Berg M.P. Postma A.V. Rook M.B. Viersma J.W. van Langen I.M. Tan-Sindhunata G. Bink-Boelkens M.T.E. van der Hout A.H. Mannens M.M.A.M. Wilde A.A.M. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ. Res. 1999 85 12 1206 1213 10.1161/01.RES.85.12.1206 10590249
    [Google Scholar]
  69. Gorący J. Gorący I. Kaczmarczyk M. Parczewski M. Cyryłowski L. Brykczyński M. Peregud-Pogorzelska M. Ciechanowicz A. VAMP-8 gene variant is associated with increased risk of early myocardial infarction. Arch. Med. Sci. 2011 3 3 440 443 10.5114/aoms.2011.23409 22295026
    [Google Scholar]
  70. Shiffman D. Rowland C.M. Louie J.Z. Luke M.M. Bare L.A. Bolonick J.I. Young B.A. Catanese J.J. Stiggins C.F. Pullinger C.R. Topol E.J. Malloy M.J. Kane J.P. Ellis S.G. Devlin J.J. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2006 26 7 1613 1618 10.1161/01.ATV.0000226543.77214.e4 16690874
    [Google Scholar]
  71. Dai X. Wiernek S. Evans J.P. Runge M.S. Genetics of coronary artery disease and myocardial infarction. World J. Cardiol. 2016 8 1 1 23 10.4330/wjc.v8.i1.1 26839654
    [Google Scholar]
  72. Manolio T.A. Boerwinkle E. O’Donnell C.J. Wilson A.F. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004 24 9 1567 1577 10.1161/01.ATV.0000138789.11433.c1 15256397
    [Google Scholar]
  73. MacArthur J. Bowler E. Cerezo M. Gil L. Hall P. Hastings E. Junkins H. McMahon A. Milano A. Morales J. Pendlington Z.M. Welter D. Burdett T. Hindorff L. Flicek P. Cunningham F. Parkinson H. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res. 2017 45 D1 D896 D901 10.1093/nar/gkw1133 27899670
    [Google Scholar]
  74. Kathiresan S. Melander O. Anevski D. Guiducci C. Burtt N.P. Roos C. Hirschhorn J.N. Berglund G. Hedblad B. Groop L. Altshuler D.M. Newton-Cheh C. Orho-Melander M. Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 2008 358 12 1240 1249 10.1056/NEJMoa0706728 18354102
    [Google Scholar]
  75. Teekakirikul P. Kelly M.A. Rehm H.L. Lakdawala N.K. Funke B.H. Inherited Cardiomyopathies. J. Mol. Diagn. 2013 15 2 158 170 10.1016/j.jmoldx.2012.09.002 23274168
    [Google Scholar]
  76. D’Argenio V. Frisso G. Precone V. Boccia A. Fienga A. Pacileo G. Limongelli G. Paolella G. Calabrò R. Salvatore F. DNA sequence capture and next-generation sequencing for the molecular diagnosis of genetic cardiomyopathies. J. Mol. Diagn. 2014 16 1 32 44 10.1016/j.jmoldx.2013.07.008 24183960
    [Google Scholar]
  77. Personalized medicine: Identifying the appropriate patient through biomarkers in oncology. P&T 2011 36 7 Suppl. 1 3 10 21931468
    [Google Scholar]
  78. Jain K.K. The Handbook of Biomarkers. Humana Press 10.1007/978‑1‑60761‑685‑6
    [Google Scholar]
  79. Huan T. Esko T. Peters M.J. Pilling L.C. Schramm K. Schurmann C. Chen B.H. Liu C. Joehanes R. Johnson A.D. Yao C. Ying S. Courchesne P. Milani L. Raghavachari N. Wang R. Liu P. Reinmaa E. Dehghan A. Hofman A. Uitterlinden A.G. Hernandez D.G. Bandinelli S. Singleton A. Melzer D. Metspalu A. Carstensen M. Grallert H. Herder C. Meitinger T. Peters A. Roden M. Waldenberger M. Dörr M. Felix S.B. Zeller T. Vasan R. O’Donnell C.J. Munson P.J. Yang X. Prokisch H. Völker U. van Meurs J.B.J. Ferrucci L. Levy D. A meta-analysis of gene expression signatures of blood pressure and hypertension. PLoS Genet. 2015 11 3 e1005035 10.1371/journal.pgen.1005035 25785607
    [Google Scholar]
  80. Tada H Fujino N Nomura A Nakanishi C Hayashi K Takamura M Personalized medicine for cardiovascular diseases. J Hum Genet 2021 66 1 67 74 10.1038/s10038‑020‑0818‑7
    [Google Scholar]
  81. Duncan K. Al-Haddad M. Arrhythmias. Springer 2023 185 194 10.1007/978‑3‑031‑21991‑7_13
    [Google Scholar]
  82. Heart arrhythmia - Symptoms and causes 2023 Available from: https://www.mayoclinic.org/diseases-conditions/heart-arrhythmia/symptoms-causes/syc-20350668
  83. S D. T T. v C. Arrhythmia’s: Types, pathophysiology and therapy: A review. IRJP 2019 10 2 23 30 10.7897/2230‑8407.100236
    [Google Scholar]
  84. Karpawich P.P. Pathophysiology of Cardiac Arrhythmias: Arrhythmogenesis and types of Arrhythmias. Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Adis Cham 2015 1003 1014 10.1007/978‑3‑319‑15961‑4_47
    [Google Scholar]
  85. Iwasaki Y. Nishida K. Kato T. Nattel S. Atrial fibrillation pathophysiology: Implications for management. Circulation 2011 124 20 2264 2274 10.1161/CIRCULATIONAHA.111.019893 22083148
    [Google Scholar]
  86. Williams M.V. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J. Clin. Pharmacol. 1984 24 4 129 147 10.1002/j.1552‑4604.1984.tb01822.x 6144698
    [Google Scholar]
  87. Parida S. Thangaswamy C. Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation. Indian J. Anaesth. 2017 61 9 712 720 10.4103/ija.IJA_383_17 28970629
    [Google Scholar]
  88. Roden D.M. Johnson J.A. Kimmel S.E. Krauss R.M. Medina M.W. Shuldiner A. Wilke R.A. Cardiovascular Pharmacogenomics. Circ. Res. 2011 109 7 807 820 10.1161/CIRCRESAHA.110.230995 21921273
    [Google Scholar]
  89. Roden D.M. Personalized medicine to treat arrhythmias. Curr. Opin. Pharmacol. 2014 15 61 67 10.1016/j.coph.2013.11.013 24721655
    [Google Scholar]
  90. Darbar D. Triggers for cardiac events in patients with type 2 long QT syndrome. Heart Rhythm 2010 7 12 1806 1807 10.1016/j.hrthm.2010.09.075 20887809
    [Google Scholar]
  91. Vincent G.M. Schwartz P.J. Denjoy I. Swan H. Bithell C. Spazzolini C. Crotti L. Piippo K. Lupoglazoff J.M. Villain E. Priori S.G. Napolitano C. Zhang L. High efficacy of beta-blockers in long-QT syndrome type 1: Contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. Circulation 2009 119 2 215 221 10.1161/CIRCULATIONAHA.108.772533 19118258
    [Google Scholar]
  92. Schwartz P.J. Ackerman M.J. George A.L. Jr Wilde A.A.M. Impact of genetics on the clinical management of channelopathies. J. Am. Coll. Cardiol. 2013 62 3 169 180 10.1016/j.jacc.2013.04.044 23684683
    [Google Scholar]
  93. Watanabe H. Chopra N. Laver D. Hwang H.S. Davies S.S. Roach D.E. Duff H.J. Roden D.M. Wilde A.A.M. Knollmann B.C. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat. Med. 2009 15 4 380 383 10.1038/nm.1942 19330009
    [Google Scholar]
  94. Husser D. Adams V. Piorkowski C. Hindricks G. Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J. Am. Coll. Cardiol. 2010 55 8 747 753 10.1016/j.jacc.2009.11.041 20170812
    [Google Scholar]
  95. Shoemaker M.B. Husser D. Roselli C. Al Jazairi M. Chrispin J. Kühne M. Neumann B. Knight S. Sun H. Mohanty S. Shaffer C. Thériault S. Rinke L.L. Siland J.E. Crawford D.M. Ueberham L. Zardkoohi O. Büttner P. Geelhoed B. Blum S. Aeschbacher S. Smith J.D. Van Wagoner D.R. Freudling R. Müller-Nurasyid M. Montgomery J. Yoneda Z. Wells Q. Issa T. Weeke P. Jacobs V. Van Gelder I.C. Hindricks G. Barnard J. Calkins H. Darbar D. Michaud G. Kääb S. Ellinor P. Natale A. Chung M. Nazarian S. Cutler M.J. Sinner M.F. Conen D. Rienstra M. Bollmann A. Roden D.M. Lubitz S. Genetic susceptibility for atrial fibrillation in patients undergoing atrial fibrillation ablation. Circ. Arrhythm. Electrophysiol. 2020 13 3 e007676 10.1161/CIRCEP.119.007676 32078373
    [Google Scholar]
  96. Body S.C. Collard C.D. Shernan S.K. Fox A.A. Liu K.Y. Ritchie M.D. Perry T.E. Muehlschlegel J.D. Aranki S. Donahue B.S. Pretorius M. Estrada J.C. Ellinor P.T. Newton-Cheh C. Seidman C.E. Seidman J.G. Herman D.S. Lichtner P. Meitinger T. Pfeufer A. Kääb S. Brown N.J. Roden D.M. Darbar D. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ. Cardiovasc. Genet. 2009 2 5 499 506 10.1161/CIRCGENETICS.109.849075 20031626
    [Google Scholar]
  97. Parvez B. Chopra N. Rowan S. Vaglio J.C. Muhammad R. Roden D.M. Darbar D. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J. Am. Coll. Cardiol. 2012 59 1 49 56 10.1016/j.jacc.2011.08.061 22192668
    [Google Scholar]
  98. Hunt D.J. Jones P.P. Wang R. Chen W. Bolstad J. Chen K. Shimoni Y. Chen S.R.W. K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem. J. 2007 404 3 431 438 10.1042/BJ20070135 17313373
    [Google Scholar]
  99. Lehnart S.E. Terrenoire C. Reiken S. Wehrens X.H.T. Song L.S. Tillman E.J. Mancarella S. Coromilas J. Lederer W.J. Kass R.S. Marks A.R. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc. Natl. Acad. Sci. USA 2006 103 20 7906 7910 10.1073/pnas.0602133103 16672364
    [Google Scholar]
  100. Thygesen K. Alpert J.S. White H.D. Jaffe A.S. Apple F.S. Galvani M. Katus H.A. Newby L.K. Ravkilde J. Chaitman B. Clemmensen P.M. Dellborg M. Hod H. Porela P. Underwood R. Bax J.J. Beller G.A. Bonow R. Van der Wall E.E. Bassand J.P. Wijns W. Ferguson T.B. Steg P.G. Uretsky B.F. Williams D.O. Armstrong P.W. Antman E.M. Fox K.A. Hamm C.W. Ohman E.M. Simoons M.L. Poole-Wilson P.A. Gurfinkel E.P. Lopez-Sendon J.L. Pais P. Mendis S. Zhu J.R. Wallentin L.C. Fernández-Avilés F. Fox K.M. Parkhomenko A.N. Priori S.G. Tendera M. Voipio-Pulkki L.M. Vahanian A. Camm A.J. De Caterina R. Dean V. Dickstein K. Filippatos G. Funck-Brentano C. Hellemans I. Kristensen S.D. McGregor K. Sechtem U. Silber S. Tendera M. Widimsky P. Zamorano J.L. Morais J. Brener S. Harrington R. Morrow D. Lim M. Martinez-Rios M.A. Steinhubl S. Levine G.N. Gibler W.B. Goff D. Tubaro M. Dudek D. Al-Attar N. Universal definition of myocardial infarction. Circulation 2007 116 22 2634 2653 10.1161/CIRCULATIONAHA.107.187397 17951284
    [Google Scholar]
  101. Reimer K.A. Jennings R.B. Tatum A.H. Pathobiology of acute myocardial ischemia: Metabolic, functional and ultrastructural studies. Am. J. Cardiol. 1983 52 2 72 81 10.1016/0002‑9149(83)90180‑7 6869259
    [Google Scholar]
  102. Apple F.S. Sandoval Y. Jaffe A.S. Ordonez-Llanos J. Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care. Clin. Chem. 2017 63 1 73 81 10.1373/clinchem.2016.255109 28062612
    [Google Scholar]
  103. Costa F.M. Ferreira J. Aguiar C. Dores H. Figueira J. Mendes M. Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years. Eur. Heart J. 2012 33 20 2544 2550 10.1093/eurheartj/ehs311 22991454
    [Google Scholar]
  104. Christia P. Frangogiannis N.G. Pathophysiology of acute myocardial infarction. Adv Myocard Infarct Manag 2013 35 46 10.2217/ebo.12.301
    [Google Scholar]
  105. Szmitko P.E. Wang C.H. Weisel R.D. Jeffries G.A. Anderson T.J. Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003 108 17 2041 2048 10.1161/01.CIR.0000089093.75585.98 14581382
    [Google Scholar]
  106. Niccoli G. Camici P.G. Myocardial infarction with non-obstructive coronary arteries: What is the prognosis? Eur. Heart J. Suppl. 2020 22 Suppl. E E40 E45 10.1093/eurheartj/suaa057 32523437
    [Google Scholar]
  107. Tamis-Holland J.E. Jneid H. Reynolds H.R. Agewall S. Brilakis E.S. Brown T.M. Lerman A. Cushman M. Kumbhani D.J. Arslanian-Engoren C. Bolger A.F. Beltrame J.F. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: A scientific statement From the American Heart Association. Circulation 2019 139 18 e891 e908 10.1161/CIR.0000000000000670 30913893
    [Google Scholar]
  108. Hayes S.N. Kim E.S.H. Saw J. Adlam D. Arslanian-Engoren C. Economy K.E. Ganesh S.K. Gulati R. Lindsay M.E. Mieres J.H. Naderi S. Shah S. Thaler D.E. Tweet M.S. Wood M.J. Spontaneous coronary artery dissection: Current state of the science: A scientific statement from the American Heart Association. Circulation 2018 137 19 e523 e557 10.1161/CIR.0000000000000564 29472380
    [Google Scholar]
  109. Lüscher T.F. Pieper M. Tendera M. Vrolix M. Rutsch W. van den Branden F. Gil R. Bischoff K.O. Haude M. Fischer D. Meinertz T. Münzel T. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: The ENCORE II study. Eur. Heart J. 2009 30 13 1590 1597 10.1093/eurheartj/ehp151 19474053
    [Google Scholar]
  110. Grootaert M.O.J. Schrijvers D.M. Van Spaendonk H. Breynaert A. Hermans N. Van Hoof V.O. Takahashi N. Vandenabeele P. Kim S.H. De Meyer G.R.Y. Martinet W. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. Atherosclerosis 2016 252 166 174 10.1016/j.atherosclerosis.2016.06.045 27425215
    [Google Scholar]
  111. Smit M. Coetzee A.R. Lochner A. The pathophysiology of myocardial ischemia and perioperative myocardial infarction. J. Cardiothorac. Vasc. Anesth. 2020 34 9 2501 2512 10.1053/j.jvca.2019.10.005 31685419
    [Google Scholar]
  112. Kumamoto M. Nakashima Y. Sueishi K. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance. Hum. Pathol. 1995 26 4 450 456 10.1016/0046‑8177(95)90148‑5 7535741
    [Google Scholar]
  113. Burke A.P. Farb A. Malcom G.T. Liang Y. Smialek J.E. Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999 281 10 921 926 10.1001/jama.281.10.921 10078489
    [Google Scholar]
  114. Bentzon J.F. Otsuka F. Virmani R. Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014 114 12 1852 1866 10.1161/CIRCRESAHA.114.302721 24902970
    [Google Scholar]
  115. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J. Am. Coll. Cardiol. 1988 12 6 Suppl. A A3 A13 10.1016/0735‑1097(88)92635‑6 2903874
    [Google Scholar]
  116. Appleby P. Baigent C. Collins R. Flather M. Parish S. Peto R. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994 343 8893 311 322 10.1016/S0140‑6736(94)91161‑4 7905143
    [Google Scholar]
  117. Roffi M. Patrono C. Collet J.P. Mueller C. Valgimigli M. Andreotti F. Bax J.J. Borger M.A. Brotons C. Chew D.P. Gencer B. Hasenfuss G. Kjeldsen K. Lancellotti P. Landmesser U. Mehilli J. Mukherjee D. Storey R.F. Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2016 37 3 267 315 10.1093/eurheartj/ehv320 26320110
    [Google Scholar]
  118. Ibanez B. James S. Agewall S. Antunes M.J. Bucciarelli-Ducci C. Bueno H. Caforio A.L.P. Crea F. Goudevenos J.A. Halvorsen S. Hindricks G. Kastrati A. Lenzen M.J. Prescott E. Roffi M. Valgimigli M. Varenhorst C. Vranckx P. Widimský P. Collet J-P. Kristensen S.D. Aboyans V. Baumbach A. Bugiardini R. Coman I.M. Delgado V. Fitzsimons D. Gaemperli O. Gershlick A.H. Gielen S. Harjola V-P. Katus H.A. Knuuti J. Kolh P. Leclercq C. Lip G.Y.H. Morais J. Neskovic A.N. Neumann F-J. Niessner A. Piepoli M.F. Richter D.J. Shlyakhto E. Simpson I.A. Steg P.G. Terkelsen C.J. Thygesen K. Windecker S. Zamorano J.L. Zeymer U. Windecker S. Aboyans V. Agewall S. Barbato E. Bueno H. Coca A. Collet J-P. Coman I.M. Dean V. Delgado V. Fitzsimons D. Gaemperli O. Hindricks G. Iung B. Jüni P. Katus H.A. Knuuti J. Lancellotti P. Leclercq C. McDonagh T. Piepoli M.F. Ponikowski P. Richter D.J. Roffi M. Shlyakhto E. Simpson I.A. Zamorano J.L. Chettibi M. Hayrapetyan H.G. Metzler B. Ibrahimov F. Sujayeva V. Beauloye C. Dizdarevic-Hudic L. Karamfiloff K. Skoric B. Antoniades L. Tousek P. Terkelsen P.C.J. Shaheen S.M. Marandi T. Niemelä M. Kedev S. Gilard M. Aladashvili A. Elsaesser A. Kanakakis I.G. Merkely B. Gudnason T. Iakobishvili Z. Bolognese L. Berkinbayev S. Bajraktari G. Beishenkulov M. Zake I. Lamin H.B. Gustiene O. Pereira B. Xuereb R.G. Ztot S. Juliebø V. Legutko J. Timóteo A.T. Tatu-Chiţoiu G. Yakovlev A. Bertelli L. Nedeljkovic M. Studenčan M. Bunc M. García de Castro A.M. Petursson P. Jeger R. Mourali M.S. Yildirir A. Parkhomenko A. Gale C.P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018 39 2 119 177 10.1093/eurheartj/ehx393 28886621
    [Google Scholar]
  119. Scott R.A. Freitag D.F. Li L. Chu A.Y. Surendran P. Young R. Grarup N. Stancáková A. Chen Y. Varga T.V. Yaghootkar H. Luan J. Zhao J.H. Willems S.M. Wessel J. Wang S. Maruthur N. Michailidou K. Pirie A. van der Lee S.J. Gillson C. Al Olama A.A. Amouyel P. Arriola L. Arveiler D. Aviles-Olmos I. Balkau B. Barricarte A. Barroso I. Garcia S.B. Bis J.C. Blankenberg S. Boehnke M. Boeing H. Boerwinkle E. Borecki I.B. Bork-Jensen J. Bowden S. Caldas C. Caslake M. Cupples L.A. Cruchaga C. Czajkowski J. den Hoed M. Dunn J.A. Earl H.M. Ehret G.B. Ferrannini E. Ferrieres J. Foltynie T. Ford I. Forouhi N.G. Gianfagna F. Gonzalez C. Grioni S. Hiller L. Jansson J.H. Jørgensen M.E. Jukema J.W. Kaaks R. Kee F. Kerrison N.D. Key T.J. Kontto J. Kote-Jarai Z. Kraja A.T. Kuulasmaa K. Kuusisto J. Linneberg A. Liu C. Marenne G. Mohlke K.L. Morris A.P. Muir K. Müller-Nurasyid M. Munroe P.B. Navarro C. Nielsen S.F. Nilsson P.M. Nordestgaard B.G. Packard C.J. Palli D. Panico S. Peloso G.M. Perola M. Peters A. Poole C.J. Quirós J.R. Rolandsson O. Sacerdote C. Salomaa V. Sánchez M.J. Sattar N. Sharp S.J. Sims R. Slimani N. Smith J.A. Thompson D.J. Trompet S. Tumino R. van der A D.L. van der Schouw Y.T. Virtamo J. Walker M. Walter K. Abraham J.E. Amundadottir L.T. Aponte J.L. Butterworth A.S. Dupuis J. Easton D.F. Eeles R.A. Erdmann J. Franks P.W. Frayling T.M. Hansen T. Howson J.M.M. Jørgensen T. Kooner J. Laakso M. Langenberg C. McCarthy M.I. Pankow J.S. Pedersen O. Riboli E. Rotter J.I. Saleheen D. Samani N.J. Schunkert H. Vollenweider P. O’Rahilly S. Deloukas P. Danesh J. Goodarzi M.O. Kathiresan S. Meigs J.B. Ehm M.G. Wareham N.J. Waterworth D.M. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci. Transl. Med. 2016 8 341 341ra76 10.1126/scitranslmed.aad3744 27252175
    [Google Scholar]
  120. Claassens D.M.F. Vos G.J.A. Bergmeijer T.O. Hermanides R.S. van ’t Hof A.W.J. van der Harst P. Barbato E. Morisco C. Tjon Joe Gin R.M. Asselbergs F.W. Mosterd A. Herrman J.P.R. Dewilde W.J.M. Janssen P.W.A. Kelder J.C. Postma M.J. de Boer A. Boersma C. Deneer V.H.M. ten Berg J.M. A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI. N. Engl. J. Med. 2019 381 17 1621 1631 10.1056/NEJMoa1907096 31479209
    [Google Scholar]
  121. Pereira N.L. Farkouh M.E. So D. Lennon R. Geller N. Mathew V. Bell M. Bae J.H. Jeong M.H. Chavez I. Gordon P. Abbott J.D. Cagin C. Baudhuin L. Fu Y.P. Goodman S.G. Hasan A. Iturriaga E. Lerman A. Sidhu M. Tanguay J.F. Wang L. Weinshilboum R. Welsh R. Rosenberg Y. Bailey K. Rihal C. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention. JAMA 2020 324 8 761 771 10.1001/jama.2020.12443 32840598
    [Google Scholar]
  122. Bhattacharya S. Granger C.B. Craig D. Haynes C. Bain J. Stevens R.D. Hauser E.R. Newgard C.B. Kraus W.E. Newby L.K. Shah S.H. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis 2014 232 1 191 196 10.1016/j.atherosclerosis.2013.10.036 24401236
    [Google Scholar]
  123. Shah R.V. Truong Q.A. Gaggin H.K. Pfannkuche J. Hartmann O. Januzzi J.L. Jr Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur. Heart J. 2012 33 17 2197 2205 10.1093/eurheartj/ehs136 22645194
    [Google Scholar]
  124. Tanzilli G. Arrivi A. Placanica A. Viceconte N. Cammisotto V. Nocella C. Barillà F. Torromeo C. Pucci G. Acconcia M.C. Granatelli A. Basili S. Dominici M. Gaudio C. Carnevale R. Mangieri E. Glutathione infusion before and 3 days after primary angioplasty blunts ongoing NOX2-mediated inflammatory response. J. Am. Heart Assoc. 2021 10 18 e020560 10.1161/JAHA.120.020560 34533039
    [Google Scholar]
  125. Ma Y. Yuan Y. Aili Z. Maitusong M. Li H. Nijiati M. Proteomics analysis of coronary blood microparticles in patients with acute myocardial infarction. Cardiol. J. 2023 30 2 286 296 10.5603/CJ.a2022.0081 36036671
    [Google Scholar]
  126. Valdes-Marquez E. Clarke R. Hill M. Watkins H. Hopewell J.C. Proteomic profiling identifies novel independent relationships between inflammatory proteins and myocardial infarction. Eur. J. Prev. Cardiol. 2023 30 7 583 591 10.1093/eurjpc/zwad020 36702559
    [Google Scholar]
  127. Pan Y. Wang L. Xie Y. Tan Y. Chang C. Qiu X. Li X. Characterization of differentially expressed plasma proteins in patients with acute myocardial infarction. J. Proteomics 2020 227 103923 10.1016/j.jprot.2020.103923 32736138
    [Google Scholar]
  128. Xie Y. Zhang H. Huang T. Quantitative proteomics reveal three potential biomarkers for risk assessment of acute myocardial infarction. Bioengineered 2022 13 3 4939 4950 10.1080/21655979.2022.2037365 35156527
    [Google Scholar]
  129. Zhan C. Tang T. Wu E. Zhang Y. He M. Wu R. Bi C. Wang J. Zhang Y. Shen B. From multi-omics approaches to personalized medicine in myocardial infarction. Front. Cardiovasc. Med. 2023 10 1250340 10.3389/fcvm.2023.1250340 37965091
    [Google Scholar]
  130. Whelton P.K. Carey R.M. Aronow W.S. Casey D.E. Jr Collins K.J. Dennison Himmelfarb C. DePalma S.M. Gidding S. Jamerson K.A. Jones D.W. MacLaughlin E.J. Muntner P. Ovbiagele B. Smith S.C. Jr Spencer C.C. Stafford R.S. Taler S.J. Thomas R.J. Williams K.A. Sr Williamson J.D. Wright J.T. Jr 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines. Hypertension 2018 71 6 e13 e115 10.1161/HYP.0000000000000065/SUPPL_FILE/DATA_SUPPLEMENT 29133356
    [Google Scholar]
  131. Aronow W.S. Fleg J.L. Pepine C.J. Artinian N.T. Bakris G. Brown A.S. Ferdinand K.C. Forciea M.A. Frishman W.H. Jaigobin C. Kostis J.B. Mancia G. Oparil S. Ortiz E. Reisin E. Rich M.W. Schocken D.D. Weber M.A. Wesley D.J. Harrington R.A. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Circulation 2011 123 21 2434 2506 10.1161/CIR.0b013e31821daaf6 21518977
    [Google Scholar]
  132. Hall J.E. do Carmo J.M. da Silva A.A. Wang Z. Hall M.E. Obesity-induced hypertension. Circ. Res. 2015 116 6 991 1006 10.1161/CIRCRESAHA.116.305697 25767285
    [Google Scholar]
  133. Padmanabhan S. Caulfield M. Dominiczak A.F. Genetic and molecular aspects of hypertension. Circ. Res. 2015 116 6 937 959 10.1161/CIRCRESAHA.116.303647 25767282
    [Google Scholar]
  134. Unger T. Borghi C. Charchar F. Khan N.A. Poulter N.R. Prabhakaran D. Ramirez A. Schlaich M. Stergiou G.S. Tomaszewski M. Wainford R.D. Williams B. Schutte A.E. 2020 international society of hypertension global hypertension practice guidelines. Hypertension 2020 75 6 1334 1357 10.1161/HYPERTENSIONAHA.120.15026 32370572
    [Google Scholar]
  135. Kowalski S. Goniewicz K. Moskal A. Al-Wathinani A.M. Goniewicz M. Symptoms in hypertensive patients presented to the emergency medical service: A comprehensive retrospective analysis in clinical settings. J Clin Med 2023 12 17 5495 10.3390/jcm12175495
    [Google Scholar]
  136. Beevers G. Lip G.Y.H. O’Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ 2001 322 7291 912 916 10.1136/bmj.322.7291.912 11302910
    [Google Scholar]
  137. te Riet L. van Esch J.H.M. Roks A.J.M. van den Meiracker A.H. Danser A.H.J. Hypertension. Circ. Res. 2015 116 6 960 975 10.1161/CIRCRESAHA.116.303587 25767283
    [Google Scholar]
  138. Morris R.C. Jr Schmidlin O. Sebastian A. Tanaka M. Kurtz T.W. RC M Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension. Circulation 2016 133 9 881 893 10.1161/CIRCULATIONAHA.115.017923
    [Google Scholar]
  139. Furberg C.D. Wright J.T. Davis B.R. Cutler J.A. Alderman M. Black H. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 288 23 2981 2997 10.1001/jama.288.23.2981 12479763
    [Google Scholar]
  140. Carey R.M. Moran A.E. Whelton P.K. Treatment of Hypertension. JAMA 2022 328 18 1849 1861 10.1001/jama.2022.19590 36346411
    [Google Scholar]
  141. Turner ST Schwartz GL Boerwinkle E Personalized medicine for high blood pressure. Hypertension 2007 50 1 1 5 10.1161/HYPERTENSIONAHA.107.087049
    [Google Scholar]
  142. McDonough C.W. Magvanjav O. Sá A.C.C. El Rouby N.M. Dave C. Deitchman A.N. Kawaguchi-Suzuki M. Mei W. Shen Y. Singh R.S.P. Solayman M. Bailey K.R. Boerwinkle E. Chapman A.B. Gums J.G. Webb A. Scherer S.E. Sadee W. Turner S.T. Cooper-DeHoff R.M. Gong Y. Johnson J.A. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ. Genom. Precis. Med. 2018 11 4 e001854 10.1161/CIRCGEN.117.001854 29650764
    [Google Scholar]
  143. Sá A.C.C. Webb A. Gong Y. McDonough C.W. Shahin M.H. Datta S. Langaee T.Y. Turner S.T. Beitelshees A.L. Chapman A.B. Boerwinkle E. Gums J.G. Scherer S.E. Cooper-DeHoff R.M. Sadee W. Johnson J.A. Blood pressure signature genes and blood pressure response to thiazide diuretics: Results from the PEAR and PEAR-2 studies. BMC Med. Genomics 2018 11 1 55 10.1186/s12920‑018‑0370‑x 29925376
    [Google Scholar]
  144. Laragh J.H. Letcher R.L. Pickering T.G. Renin profiling for diagnosis and treatment of hypertension. JAMA 1979 241 2 151 156 10.1001/jama.1979.03290280031022 31492
    [Google Scholar]
  145. Rydberg D.M. Mejyr S. Loikas D. Schenck-Gustafsson K. von Euler M. Malmström R.E. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur. J. Clin. Pharmacol. 2018 74 9 1165 1173 10.1007/s00228‑018‑2480‑y 29804162
    [Google Scholar]
  146. Brewster L.M. Seedat Y.K. Why do hypertensive patients of African ancestry respond better to calciumblockers and diuretics than to ACE inhibitors and β-adrenergic blockers? Asystematic review. BMC Med. 2013 11 1 141 10.1186/1741‑7015‑11‑141 23721258
    [Google Scholar]
  147. Cooper-DeHoff R.M. Johnson J.A. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat. Rev. Nephrol. 2016 12 2 110 122 10.1038/nrneph.2015.176 26592190
    [Google Scholar]
  148. Natarajan P. Young R. Stitziel N.O. Padmanabhan S. Baber U. Mehran R. Sartori S. Fuster V. Reilly D.F. Butterworth A. Rader D.J. Ford I. Sattar N. Kathiresan S. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 2017 135 22 2091 2101 10.1161/CIRCULATIONAHA.116.024436 28223407
    [Google Scholar]
  149. Knowles J.W. Ashley E.A. Cardiovascular disease: The rise of the genetic risk score. PLoS Med. 2018 15 3 e1002546 10.1371/journal.pmed.1002546 29601582
    [Google Scholar]
  150. Araujo A. Julious S. Senn S. Understanding variation in sets of N-of-1 trials. PLoS One 2016 11 12 e0167167 10.1371/journal.pone.0167167 27907056
    [Google Scholar]
  151. Ischemic Heart Disease. National Academies Press US 2010
    [Google Scholar]
  152. Opie L.H. Angina pectoris: The evolution of concepts. J. Cardiovasc. Pharmacol. Ther. 2004 9 1_suppl Suppl. 1 S3 S9 10.1177/107424840400900102 15378128
    [Google Scholar]
  153. Balla C. Pavasini R. Ferrari R. Treatment of Angina: Where are we? Cardiology 2018 140 1 52 67 10.1159/000487936 29874661
    [Google Scholar]
  154. Rousan T.A. Thadani U. Stable Angina medical therapy management guidelines: A critical review of guidelines from the european society of cardiology and national institute for health and care excellence. Eur. Cardiol. 2019 14 1 18 22 10.15420/ecr.2018.26.1 31131033
    [Google Scholar]
  155. Wee Y. Burns K. Bett N. Medical management of chronic stable angina. Aust. Prescr. 2015 38 4 131 136 10.18773/austprescr.2015.042 26648642
    [Google Scholar]
  156. Silva F.M.F. Pesaro A.E.P. Franken M. Wajngarten M. Acute management of unstable angina and non-ST segment elevation myocardial infarction. Einstein 2015 13 3 454 461 10.1590/S1679‑45082015RW3172
    [Google Scholar]
  157. Yusuf S. Zhao F. Mehta S.R. Chrolavicius S. Tognoni G. Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001 345 7 494 502 10.1056/NEJMoa010746 11519503
    [Google Scholar]
  158. Mega J.L. Stitziel N.O. Smith J.G. Chasman D.I. Caulfield M.J. Devlin J.J. Nordio F. Hyde C.L. Cannon C.P. Sacks F.M. Poulter N.R. Sever P.S. Ridker P.M. Braunwald E. Melander O. Kathiresan S. Sabatine M.S. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials. Lancet 2015 385 9984 2264 2271 10.1016/S0140‑6736(14)61730‑X 25748612
    [Google Scholar]
  159. Iakoubova O.A. Tong C.H. Rowland C.M. Kirchgessner T.G. Young B.A. Arellano A.R. Shiffman D. Sabatine M.S. Campos H. Packard C.J. Pfeffer M.A. White T.J. Braunwald E. Shepherd J. Devlin J.J. Sacks F.M. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 2008 51 4 435 443 10.1016/j.jacc.2007.05.057 18222353
    [Google Scholar]
  160. Carbone F. Montecucco F. Mach F. Update on evidence for treatment with ranolazine in stable angina. Swiss Med. Wkly. 2013 143 w13874 w13874 10.4414/smw.2013.13874 24163124
    [Google Scholar]
  161. Iqbal J. Serruys P.W. Revascularization strategies for patients with stable coronary artery disease. J. Intern. Med. 2014 276 4 336 351 10.1111/joim.12243 24690076
    [Google Scholar]
  162. Gajare S.R. Deshmukh A.S. Shinde C.K. Personalized medicine: A review. Int. J. Pharm. Sci. Rev. Res. 2021 69 1 10.47583/ijpsrr.2021.v69i01.023
    [Google Scholar]
  163. Stefanicka-Wojtas D. Kurpas D. Personalised medicine—implementation to the healthcare system in Europe (focus group discussions). J. Pers. Med. 2023 13 3 380 10.3390/jpm13030380 36983562
    [Google Scholar]
  164. Lerman A. Zeiher A.M. Endothelial Function. Circulation 2005 111 3 363 368 10.1161/01.CIR.0000153339.27064.14 15668353
    [Google Scholar]
  165. Rubinshtein R. Yang E.H. Rihal C.S. Prasad A. Lennon R.J. Best P.J. Lerman L.O. Lerman A. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur. Heart J. 2010 31 8 936 942 10.1093/eurheartj/ehp459 19897496
    [Google Scholar]
  166. Rubinshtein R. Kuvin J.T. Soffler M. Lennon R.J. Lavi S. Nelson R.E. Pumper G.M. Lerman L.O. Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur. Heart J. 2010 31 9 1142 1148 10.1093/eurheartj/ehq010 20181680
    [Google Scholar]
  167. Hamburg N.M. Keyes M.J. Larson M.G. Vasan R.S. Schnabel R. Pryde M.M. Mitchell G.F. Sheffy J. Vita J.A. Benjamin E.J. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008 117 19 2467 2474 10.1161/CIRCULATIONAHA.107.748574 18458169
    [Google Scholar]
  168. McCrea C.E. Skulas-Ray A.C. Chow M. West S.G. Test–retest reliability of pulse amplitude tonometry measures of vascular endothelial function: Implications for clinical trial design. Vasc. Med. 2012 17 1 29 36 10.1177/1358863X11433188 22363016
    [Google Scholar]
  169. Splawski I. Timothy K.W. Tateyama M. Clancy C.E. Malhotra A. Beggs A.H. Cappuccio F.P. Sagnella G.A. Kass R.S. Keating M.T. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002 297 5585 1333 1336 10.1126/science.1073569 12193783
    [Google Scholar]
  170. Erdmann J. Linsel-Nitschke P. Schunkert H. Genetic causes of myocardial infarction: New insights from genome-wide association studies. Dtsch. Arztebl. Int. 2010 107 40 694 699 10.3238/arztebl.2010.0694 21031128
    [Google Scholar]
  171. Dugas C.M. Schussler J.M. Advanced technology in interventional cardiology: A roadmap for the future of precision coronary interventions. Trends Cardiovasc. Med. 2016 26 5 466 473 10.1016/j.tcm.2016.02.003 27020905
    [Google Scholar]
  172. Kramer B.S. Croswell J.M. Cancer screening: The clash of science and intuition. Annu. Rev. Med. 2009 60 1 125 137 10.1146/annurev.med.60.101107.134802 18803476
    [Google Scholar]
  173. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003 348 6 529 537 10.1056/NEJMra020021 12571261
    [Google Scholar]
  174. Hamburg M.A. Collins F.S. The path to personalized medicine. N. Engl. J. Med. 2010 363 4 301 304 10.1056/NEJMp1006304 20551152
    [Google Scholar]
  175. Harrison R. Harrison’S Principles of Internal Medicine. McGraw-Hill Education 17th ed 2008
    [Google Scholar]
  176. Johnson J.A. Lima J.J. Drug receptor/effector polymorphisms and pharmacogenetics. Pharmacogenetics 2003 13 9 525 534 10.1097/00008571‑200309000‑00001 12972951
    [Google Scholar]
  177. Califf R.M. Ginsburg G.S. Organizational improvements to enhance modern clinical epidemiology. JAMA 2008 300 19 2300 2302 10.1001/jama.2008.638 19017917
    [Google Scholar]
  178. Abrahams E. Silver M. The case for personalized medicine. J. Diabetes Sci. Technol. 2009 3 4 680 684 10.1177/193229680900300411 20144313
    [Google Scholar]
  179. Cardiovascular diseases.
    [Google Scholar]
/content/journals/chddt/10.2174/011871529X361429250215190129
Loading
Treating Cardiovascular Disorders with Personalized Medicine
Bentham Science Publishers ; https://doi.org/10.2174/011871529X361429250215190129
/content/journals/chddt/10.2174/011871529X361429250215190129
/content/journals/chddt/10.2174/011871529X361429250215190129
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: personalized cardiology ; proteomics ; genomics ; bioinformatics ; Cardiovascular disorders

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test